Strober B - Search Results

1

Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.

Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. Among authors: strober b. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885

2

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Menter A, et al. Among authors: strober be. J Am Acad Dermatol. 2008 Jan;58(1):106-15. doi: 10.1016/j.jaad.2007.09.010. Epub 2007 Oct 23. J Am Acad Dermatol. 2008. PMID: 17936411 Clinical Trial.

3

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.

Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Strober BE, et al. J Am Acad Dermatol. 2011 Apr;64(4):671-81. doi: 10.1016/j.jaad.2010.03.009. J Am Acad Dermatol. 2011. PMID: 21414495 Clinical Trial.

4

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.

Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. Leonardi C, et al. Among authors: strober b. Am J Clin Dermatol. 2011 Oct 1;12(5):321-37. doi: 10.2165/11587890-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21834597 Review.

5

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. Gordon KB, et al. Among authors: strober be. J Invest Dermatol. 2012 Feb;132(2):304-14. doi: 10.1038/jid.2011.304. Epub 2011 Oct 20. J Invest Dermatol. 2012. PMID: 22011907 Free article. Clinical Trial.

6

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G. Gottlieb AB, et al. Among authors: strober be. Br J Dermatol. 2012 Sep;167(3):649-57. doi: 10.1111/j.1365-2133.2012.11015.x. Br J Dermatol. 2012. PMID: 22533447 Free PMC article. Clinical Trial.

7

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Papp KA, et al. Among authors: strober b. Br J Dermatol. 2012 Sep;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.x. Br J Dermatol. 2012. PMID: 22924949 Clinical Trial.

8

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee. Papp KA, et al. Among authors: strober b. J Drugs Dermatol. 2012 Oct;11(10):1210-7. J Drugs Dermatol. 2012. PMID: 23134986

9

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Langley RG, et al. Among authors: strober b. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16. J Eur Acad Dermatol Venereol. 2013. PMID: 23157612

10

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Papp KA, et al. Among authors: strober b. Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214. Br J Dermatol. 2013. PMID: 23301632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

261 results

Search Page